Clinical Trials Logo

Refractory Leukemia clinical trials

View clinical trials related to Refractory Leukemia.

Filter by:

NCT ID: NCT04684472 Recruiting - Clinical trials for Refractory B-Cell Non-Hodgkin Lymphoma

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Start date: March 17, 2021
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the safety and tolerance of modified CD19 CAR T cells in treating refractory/relapsed B-cell malignancies. CAR-T cells will be investigated as a single agent both in relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) and up to 60% of patients with B-cell non-Hodgkin's lymphoma (NHL).

NCT ID: NCT04470947 Recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

EXALT-2
Start date: June 10, 2020
Phase:
Study type: Observational [Patient Registry]

EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice

NCT ID: NCT04282811 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Start date: July 24, 2020
Phase:
Study type: Observational

Observational study aimed at describing the characteristics and outcome of CLL patients who started treatment with venetoclax-based regimens according to the local label outside clinical trials in Italy in a period of time ranging from the start of the Venetoclax Named Patient Program (March 2016) until October 31st, 2021.

NCT ID: NCT03799224 Recruiting - Clinical trials for Stem Cell Transplant Complications

Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia

Start date: December 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of transplant failure. We reported previously that patients with relapse or refractory AL were at very high risk of relapse post allo-HSCT, with cumulative relapse rate of 50-80%. Decitabine has been demonstrated efficacy in the treatment of patients with recurrent or refractory leukemia and myelodysplastic syndrome. It was reported that the combination of decitabine, with busulfan and cyclophosphamide as a preparative regimen for allo-HSCT using HLA-matching donors was safe and effective. In this prospective, single-arm clinical trial, we aimed to examine the efficacy of combining decitabine with modified busulfan and cyclophosphamide (mBU/CY) as a preparative regimen for allo-HSCT in recurrent and refractory AL patients.